Add this topic to your myFT Digest for news straight to your inbox
While pandemic risk is low, scientists say urgent investigations into the virus are necessary
For stretched public health budgets, high-tech treatments are hard to afford but some pre-emptive measures can prove good value
Wellcome’s John-Arne Røttingen says divisions risk harming action on pandemic responses and ‘superbugs’
Now is not a time for paranoia but there is a case for extreme vigilance
Global warming, flooding and pollution could all help promote evolution of pathogens
Habitat encroachment means more opportunities for animal-to-human infection
Changing climate and human population shifts have spread and strengthened foothold
The FT’s fifth annual ranking of the region’s businesses by revenue growth. Plus: outsourcers tap into remote work boom; Shopify targets more growth from bigger clients; Brazil’s alternative to electric vehicles; and Vertex Pharmaceutical’s potential answer to the opioid crisis
Technique devised for Timothy syndrome could open way to therapies for other untreatable conditions
Technique highlights concerns shifting global disease burden as populations age
High costs and concerns over efficacy and side effects limit uptake of first treatment as another nears approval
Research harnesses power of generative artificial intelligence in latest sign of its potential use in medicine
Study results could encourage US Medicare system and private insurers to cover tirzepatide treatments
UK research highlights risk of over-diagnosis and gaps in spotting serious variants of the disease
The idea that the technology might accelerate general human capabilities remains fanciful
Growing number of countries are also considering whether to amend legislation
Research forecasts global deaths from the disease will almost double in 20 years
It aims to exploit its extraordinary cache of genetic data but changing corporate DNA is hard
WHO member states are struggling to agree the terms of the first global treaty to deal with the threat of another Covid-19
Patients who took Sanofi’s lixisenatide experienced no worsening of motor symptoms
Not only is the cost-benefit ratio unbeatable, but not to undertake this spending is to court disaster
Chemotherapy can target microscopic cells to prevent the disease from spreading
Four years after lockdowns began we are still learning about pandemic hangovers
Funding needed to drive innovation and make therapies available to all, says co-discoverer Jennifer Doudna
Lenmeldy gene therapy treats MLD, a condition that attacks the central nervous system of young children
International Edition